WO2000001409A3 - Porcine circovirus and parvovirus vaccine - Google Patents

Porcine circovirus and parvovirus vaccine Download PDF

Info

Publication number
WO2000001409A3
WO2000001409A3 PCT/EP1999/004698 EP9904698W WO0001409A3 WO 2000001409 A3 WO2000001409 A3 WO 2000001409A3 EP 9904698 W EP9904698 W EP 9904698W WO 0001409 A3 WO0001409 A3 WO 0001409A3
Authority
WO
WIPO (PCT)
Prior art keywords
porcine circovirus
porcine
parvovirus vaccine
parvovirus
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/004698
Other languages
French (fr)
Other versions
WO2000001409A2 (en
Inventor
Gordon Moore Allan
Brian Martin Meehan
John Albert Ellis
George Steven Krakowka
Jean-Christophe Franc Audonnet
Francis Mcneilly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Saskatchewan
Boehringer Ingelheim Animal Health France SAS
Queen's University Belfast
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
University of Saskatchewan
Merial SAS
Queen's University Belfast
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Saskatchewan, Merial SAS, Queen's University Belfast, Merial Inc filed Critical University of Saskatchewan
Priority to DE69941843T priority Critical patent/DE69941843D1/en
Priority to MXPA00012785A priority patent/MXPA00012785A/en
Priority to EP99932831A priority patent/EP1094837B1/en
Priority to DK99932831.3T priority patent/DK1094837T3/en
Priority to AT99932831T priority patent/ATE452653T1/en
Priority to JP2000557855A priority patent/JP4749547B2/en
Priority to BRPI9911870A priority patent/BRPI9911870B8/en
Priority to CA2332627A priority patent/CA2332627C/en
Priority to HU0102770A priority patent/HU227805B1/en
Priority to AU49077/99A priority patent/AU746234B2/en
Priority to UA2001020808A priority patent/UA72891C2/en
Publication of WO2000001409A2 publication Critical patent/WO2000001409A2/en
Publication of WO2000001409A3 publication Critical patent/WO2000001409A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/815—Viral vaccine for porcine species, e.g. swine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to antigenic preparations and vaccines directed against the porcine multisystemic wasting syndrome (PMWS), comprising at least one porcine circovirus antigen, preferably type II, and at least one porcine parvovirus antigen.
PCT/EP1999/004698 1998-07-06 1999-06-28 Porcine circovirus and parvovirus vaccine Ceased WO2000001409A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DE69941843T DE69941843D1 (en) 1998-07-06 1999-06-28 PIG CIRCOVIRUS AND PARVOVIRUS VACCINE
MXPA00012785A MXPA00012785A (en) 1998-07-06 1999-06-28 Porcine circovirus and parvovirus vaccine.
EP99932831A EP1094837B1 (en) 1998-07-06 1999-06-28 Porcine circovirus and parvovirus vaccine
DK99932831.3T DK1094837T3 (en) 1998-07-06 1999-06-28 Porcine circovirus and parvovirus vaccine
AT99932831T ATE452653T1 (en) 1998-07-06 1999-06-28 SWINE CIRCOVIRUS AND PARVOVIRUS VACCINE
JP2000557855A JP4749547B2 (en) 1998-07-06 1999-06-28 Porcine circovirus and parvovirus vaccine
BRPI9911870A BRPI9911870B8 (en) 1998-07-06 1999-06-28 swine parvovirus and circovirus vaccine
CA2332627A CA2332627C (en) 1998-07-06 1999-06-28 Porcine circovirus and parvovirus vaccine
HU0102770A HU227805B1 (en) 1998-07-06 1999-06-28 Porcine circovirus and parvovirus vaccine
AU49077/99A AU746234B2 (en) 1998-07-06 1999-06-28 Porcine circovirus and parvovirus vaccine
UA2001020808A UA72891C2 (en) 1998-07-06 1999-06-28 Antigenic preparations comprising antigens of porcine circovirus and parvovirus and vaccines against porcine multisystemic wasting syndrome (pmws)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9808777A FR2781159B1 (en) 1998-07-06 1998-07-06 CIRCOVIRUS VACCINE AND PIG PARVOVIRUS
FR98/08777 1998-07-06

Publications (2)

Publication Number Publication Date
WO2000001409A2 WO2000001409A2 (en) 2000-01-13
WO2000001409A3 true WO2000001409A3 (en) 2000-06-29

Family

ID=9528441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/004698 Ceased WO2000001409A2 (en) 1998-07-06 1999-06-28 Porcine circovirus and parvovirus vaccine

Country Status (22)

Country Link
US (2) US6217883B1 (en)
EP (1) EP1094837B1 (en)
JP (2) JP4749547B2 (en)
KR (1) KR100730336B1 (en)
CN (1) CN1168502C (en)
AT (1) ATE452653T1 (en)
AU (1) AU746234B2 (en)
BR (1) BRPI9911870B8 (en)
CA (1) CA2332627C (en)
CY (1) CY1110290T1 (en)
DE (1) DE69941843D1 (en)
DK (1) DK1094837T3 (en)
ES (1) ES2338616T3 (en)
FR (1) FR2781159B1 (en)
HU (1) HU227805B1 (en)
MX (1) MXPA00012785A (en)
PL (1) PL205299B1 (en)
PT (1) PT1094837E (en)
RU (1) RU2237492C2 (en)
TW (1) TWI221774B (en)
UA (1) UA72891C2 (en)
WO (1) WO2000001409A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560278B2 (en) 2001-03-27 2009-07-14 University Of Saskatchewan Methods to culture circovirus
US8916353B2 (en) 1997-12-05 2014-12-23 Zoetis W Llc Circovirus sequences associated with piglet weight loss disease (PWD)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US7192594B2 (en) * 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
UA78180C2 (en) * 1997-10-03 2007-03-15 Меріаль Porcine circovirus, vaccines and diagnostic reagents
FR2781159B1 (en) * 1998-07-06 2000-10-06 Merial Sas CIRCOVIRUS VACCINE AND PIG PARVOVIRUS
US7211379B2 (en) * 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US20040062775A1 (en) * 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
JP3795751B2 (en) * 1997-12-11 2006-07-12 ユニバーシティ オブ サスカッチェワン Postweaning multiple systemic wasting syndrome virus from pigs
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
ES2170622B1 (en) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas CLONES AND INFECTIVE VECTORS DERIVED FROM CORONAVIRUS AND ITS APPLICATIONS.
DE10044648A1 (en) * 2000-09-08 2002-03-21 Aventis Behring Gmbh Process for the propagation or removal of Cirocoviruses from biological material
US20030096377A1 (en) * 2001-06-28 2003-05-22 Virginia Tech Intellectual Properties, Inc. Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
RU2212898C1 (en) * 2002-02-11 2003-09-27 Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных "vl-94" strain of porcine parvovirus for manufacturing vaccine preparations
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
EP2390352A1 (en) 2003-03-18 2011-11-30 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US20040258700A1 (en) * 2003-06-23 2004-12-23 Frimann Tine Holland Vaccine formulation with a preservative
MXPA06005424A (en) 2003-11-13 2007-01-25 Univ Georgia Res Found Methods of characterizing infectious bursal disease virus.
CA2556911C (en) 2004-02-19 2013-07-30 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
UA95602C2 (en) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Pcv2 immunogenic compositions and methods of producing such compositions
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
RU2620968C9 (en) * 2004-12-30 2017-08-08 Берингер Ингельгейм Ветмедика, Инк. Pcv2 immunogenic compositions and methods of such compositions production
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
ES2343270T3 (en) 2005-04-25 2010-07-27 Merial Ltd. VACCINES AGAINST VIRUS NIPAH.
TW200643171A (en) * 2005-06-07 2006-12-16 Temasek Life Sciences Lab Ltd Porcine circovirus type 2 vaccines
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
KR100693077B1 (en) * 2005-11-03 2007-03-12 채찬희 Biological composition for the prevention and treatment of swine complex respiratory diseases
EP1951751B1 (en) 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
CA2635430A1 (en) * 2005-12-29 2007-08-23 Boehringer Ingelheim Vetmedica, Inc. Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
DK2275132T3 (en) * 2005-12-29 2021-05-17 Boehringer Ingelheim Animal Health Usa Inc MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PREPARING THEM
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
CA2664783A1 (en) * 2006-10-05 2008-10-23 Cerebus Biologicals, Inc. Methods for treating, preventing and diagnosing porcine ttv infection
WO2008064299A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
WO2008073464A2 (en) * 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
PT2094872T (en) * 2006-12-15 2017-04-27 Boehringer Ingelheim Vetmedica Inc Treatment of anti-pcv2 antibody seropositive pigs with pcv2 antigen
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
CN101294224B (en) * 2007-05-08 2011-04-06 深圳太太基因工程有限公司 Primer and probe sequence for testing pig parvoviral nucleotide fragment
AU2008294036A1 (en) * 2007-05-30 2009-03-05 Wyeth Llc Raccoon poxvirus expressing genes of porcine virus
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
CA2710247C (en) * 2007-12-21 2014-02-18 Wyeth Llc Methods and compositions for immunizing pigs against porcine circovirus
CN101932336B (en) * 2007-12-31 2014-07-09 贝林格尔.英格海姆维特梅迪卡有限公司 Pcv2 orf2 virus like particle with foreign amino acid insertion
KR20100113582A (en) 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
EP2254595A4 (en) * 2008-02-15 2012-12-05 Boehringer Ingelheim Vetmed METHOD AND COMPOSITIONS FOR REDUCING THE EFFECTS OF STOMACH DISEASES
US7927586B2 (en) * 2008-07-08 2011-04-19 South Dakota State University Vaccine for porcine post-weaning diarrhea caused by enterotoxigenic Escherichia coli
US8871220B2 (en) 2009-04-03 2014-10-28 Merial Limited Newcastle disease virus vectored avian vaccines
TWI627281B (en) * 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 Methods of reducing viricidal activity in pcv-2 compositions and pcv-2 compositions with an improved immunogenicity
US8986706B2 (en) 2010-08-31 2015-03-24 Merial, Inc. Newcastle disease virus vectored herpesvirus vaccines
CN101947318B (en) * 2010-09-09 2012-09-05 扬州优邦生物制药有限公司 Method for preparing porcine parvovirus inactivated vaccines
TWI508974B (en) 2010-12-22 2015-11-21 Sbc Virbac Ltd Porcine Circovirus Type 2, immunological composition containing the same, test kit and application thereof
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
WO2012138789A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
JP6407714B2 (en) 2011-04-25 2018-10-17 アドヴァンスド バイオサイエンス ラボラトリーズ インコーポレイテッド Truncated HIV envelope protein (ENV), methods and compositions related thereto
ES2674439T3 (en) 2011-06-01 2018-06-29 Merial, Inc. Needle-free administration of VSRRP vaccines
CA2844927C (en) 2011-08-12 2017-10-31 Merial Limited Vacuum-assisted preservation of biological products, in particular of vaccines
UA113192C2 (en) 2011-12-06 2016-12-26 IMMUNOGENIC COMPOSITION AGAINST PIG TYPE 2 (PCV2) CIRCULOSIS
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
CN105749273A (en) * 2012-01-13 2016-07-13 普莱柯生物工程股份有限公司 Bivalent inactivated vaccine for porcine circovirus type 2 and porcine parvovirus and preparation method thereof
CN102961742A (en) * 2012-01-13 2013-03-13 普莱柯生物工程股份有限公司 Bivalent inactivated vaccine of porcine circovirus type 2 and porcine parvovirus and preparation method thereof
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
CN102719407B (en) * 2012-05-25 2013-09-04 中国农业科学院哈尔滨兽医研究所 Porcine parvovirus BQ-C strain and application of porcine parvovirus BQ-C strain in preparation of inactivated porcine parvovirus vaccine
US9556419B2 (en) 2013-03-12 2017-01-31 Merial Inc. Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof
EP2994162B1 (en) 2013-05-08 2021-04-07 Pharmgate Biologics Inc. Vaccine for pcv2 and mycoplasma
CA2925281C (en) * 2013-09-25 2022-05-03 Zoetis Services Llc Pcv2b divergent vaccine composition and methods of use
ES2778425T3 (en) 2013-10-02 2020-08-10 Boehringer Ingelheim Animal Health Usa Inc PCV2 ORF2 protein variant and virus-like particles composed of it
PL3076996T3 (en) * 2013-12-03 2020-05-18 Intervet International B.V. Vaccine against porcine circo virus type 2
CN104250640A (en) 2014-08-22 2014-12-31 普莱柯生物工程股份有限公司 Porcine pseudorabies virus gene deletion strain, vaccine composition, preparation method and application thereof
AU2015343369B2 (en) 2014-11-03 2018-11-22 Georgia Tech Research Corporation Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
CN105087506B (en) * 2015-03-20 2020-06-30 普莱柯生物工程股份有限公司 A kind of porcine pseudorabies virus weakening method, its weakened virus strain, vaccine composition and application
HK1252427A1 (en) 2015-05-14 2019-05-24 Boehringer Ingelheim Animal Health USA Inc. Method for porcine circovirus production and pcv2 vaccines
PH12017502380B1 (en) 2015-06-23 2022-10-26 Merial Inc Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
BR112018069219A2 (en) 2016-03-23 2019-01-22 Intervet Int Bv a vaccine for intradermal application against pcv2 and prrs virus infection
CN106435016B (en) * 2016-08-30 2019-07-26 中国农业科学院兰州兽医研究所 A kind of LAMP kit of quick colour-developing one-step method detection porcine circovirus 2 type
UA130511C2 (en) 2016-11-03 2026-03-11 Бьорінгер Інгельхайм Ветмедіка Гмбх Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003658A1 (en) * 1996-07-19 1998-01-29 Merial Polynucleotide vaccine formula for treating porcine respiratory and reproductive diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1538305A1 (en) 1987-07-21 1994-12-15 Всесоюзный государственный научно-контрольный институт ветеринарных препаратов Госагропрома СССР Associated vaccine against peptospirosis and parvovirus infection of pigs
US5811103A (en) * 1989-03-19 1998-09-22 Akzo Nobel N.V. Hog cholera virus vaccine and diagnostic
ES2026827A6 (en) * 1991-03-26 1992-05-01 Ercros Sa Method for producing a subunit vaccine against porcine parvovirus.
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2781159B1 (en) * 1998-07-06 2000-10-06 Merial Sas CIRCOVIRUS VACCINE AND PIG PARVOVIRUS
UA78180C2 (en) * 1997-10-03 2007-03-15 Меріаль Porcine circovirus, vaccines and diagnostic reagents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003658A1 (en) * 1996-07-19 1998-01-29 Merial Polynucleotide vaccine formula for treating porcine respiratory and reproductive diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B.M. MEEHAN ET AL.: "CHARACTERIZATION OF NOVEL CIRCOVIRUS DNAS ASSOCIATED WITH WASTING SYNDROMES IN PIGS", JOURNAL OF GENERAL VIROLOGY, vol. 79, no. 9, 1998, pages 2171 - 2179, XP002099702 *
DATABASE WPI Section Ch Week 9529, Derwent World Patents Index; Class B04, AN 95-222945, XP002099703 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916353B2 (en) 1997-12-05 2014-12-23 Zoetis W Llc Circovirus sequences associated with piglet weight loss disease (PWD)
US7560278B2 (en) 2001-03-27 2009-07-14 University Of Saskatchewan Methods to culture circovirus

Also Published As

Publication number Publication date
TWI221774B (en) 2004-10-11
WO2000001409A2 (en) 2000-01-13
AU746234B2 (en) 2002-04-18
ES2338616T3 (en) 2010-05-10
JP4749547B2 (en) 2011-08-17
US6953581B2 (en) 2005-10-11
PL345948A1 (en) 2002-01-14
AU4907799A (en) 2000-01-24
US20020146431A1 (en) 2002-10-10
HUP0102770A3 (en) 2004-10-28
CN1311690A (en) 2001-09-05
HU227805B1 (en) 2012-03-28
KR20010081991A (en) 2001-08-29
UA72891C2 (en) 2005-05-16
CA2332627C (en) 2010-06-01
KR100730336B1 (en) 2007-06-19
EP1094837A2 (en) 2001-05-02
RU2237492C2 (en) 2004-10-10
JP2010222359A (en) 2010-10-07
MXPA00012785A (en) 2002-04-24
CY1110290T1 (en) 2015-01-14
DE69941843D1 (en) 2010-02-04
BRPI9911870B8 (en) 2015-09-22
BR9911870B1 (en) 2014-08-12
JP2003522106A (en) 2003-07-22
CA2332627A1 (en) 2000-01-13
CN1168502C (en) 2004-09-29
DK1094837T3 (en) 2010-04-12
ATE452653T1 (en) 2010-01-15
BR9911870A (en) 2001-03-27
PT1094837E (en) 2010-03-18
FR2781159B1 (en) 2000-10-06
EP1094837B1 (en) 2009-12-23
US6217883B1 (en) 2001-04-17
HUP0102770A2 (en) 2001-11-28
PL205299B1 (en) 2010-04-30
FR2781159A1 (en) 2000-01-21

Similar Documents

Publication Publication Date Title
PL345948A1 (en) Porcine circovirus and parvovirus vaccine
AU5562798A (en) Recombinant live avian vaccine, using as vector the avian infectious laryngotracheitis virus.
IS4518A (en) New vaccine formulation
UY26555A1 (en) PHARMACEUTICAL COMPOSITION FOR IMMUNOLOGICAL MODULATION AND PREPARATION OF VACCINES
WO1998013500A3 (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
WO2000002522A3 (en) Anthrax vaccine
AU3448797A (en) Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus
AU1436401A (en) RepO-associated virus AAV REP78 major regulatory protein, mutants thereof and uses thereof
WO2007068907A3 (en) Vaccine compositions comprising a saponin adjuvant
DK1113816T3 (en) The influenza virus vaccine composition
AU6217798A (en) Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus
ITTO20000539A0 (en) ARMREST FOR CHAIR, ARMCHAIR OR SIMILAR, AND CHAIR USING SUCH ARMREST.
EP2263689A3 (en) Chimeric infectious DNA clones of porcine circovirus and uses thereof
AUPR011700A0 (en) Composition comprising immunogenic virus sized particles (VSP)
PT2184071T (en) Capsular polysaccharide solubilisation and combination vaccines
WO2001068129A3 (en) Adjuvant for vaccines
AU7501898A (en) Live attenuated virus vaccines for equine encephalitis viruses
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
WO2004091524A3 (en) Respiratory virus vaccines
FR2769322B1 (en) NEW PORCINE CIRCOVIRUSES, VACCINES AND DIAGNOSTIC REAGENTS
WO2001096370A3 (en) Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
EP1749885B8 (en) Infectious and attenuated bovine viral diarrhea virus vaccine
ITRM20000266A0 (en) IMPROVED PROCESS FOR THE PREPARATION OF (E,Z) 3-(2-AMINOETHOXYMINO)-ANDROSTAN-6, 17-DION AND ITS ANALOGUES.
BR9915703B1 (en) recombinant rabies virus mutant, and, live attenuated rabies vaccine.
AU2002342949A1 (en) Vaccine composition comprising at least two valences, one with enhanced adjuvant and not the other

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99809131.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999932831

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/012785

Country of ref document: MX

Ref document number: 49077/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2332627

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2000 557855

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017000182

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999932831

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017000182

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 49077/99

Country of ref document: AU